‘retatrutide’ directory
- See Also
- Links
- “Lilly’s Triple Agonist, Retatrutide, Delivered Powerful Weight Loss in Pivotal Phase 3 Obesity Trial”, Lilly 2026
- “Adventures in Dieting: How Can You Tell When the Battle Is over [Retatrutide Defeats Fad Diets]”, Schorno 2026
- “The Power of Three: Retatrutide’s Role in Modern Obesity and Diabetes Therapy”, Abdul-Rahman et al 2024
- “‘Skinny Jabs’: Weight-Loss Drugs Set for New Boom As Generic Liraglutide Versions Emerge”, Davis & Kollewe 2024
- “Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease: a Randomized Phase 2a Trial”, Sanyal et al 2024
- “A Revolution in Obesity Treatment”, Lingvay & Agarwal 2023
- “Goodbye, Ozempic: A New Class of Drugs Is Transforming Obesity Care. They Are Not All the Same”, Engber 2023
- “Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial: Supplement”, Jastreboff 2023
- “Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial”, Jastreboff et al 2023
- “Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People With Type 2 Diabetes: a Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Phase 2 Trial Conducted in the USA”, Rosenstock et al 2023
- xKloc @ "2022-12-13"
- “Retatrutide, a Novel Triple GIP, GLP-1, and Glucagon Receptor Agonist in People With Type 2 Diabetes: a Phase 1b, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Multiple-Ascending Dose Trial”, Urva et al 2022
- “LY3437943, a Novel Triple Glucagon, GIP, and GLP-1 Receptor Agonist for Glycemic Control and Weight Loss: From Discovery to Clinical Proof of Concept”, Coskun et al 2022
- Sort By Magic
- Wikipedia (3)
- Miscellaneous
- Bibliography
See Also
Links
“Lilly’s Triple Agonist, Retatrutide, Delivered Powerful Weight Loss in Pivotal Phase 3 Obesity Trial”, Lilly 2026
Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
“Adventures in Dieting: How Can You Tell When the Battle Is over [Retatrutide Defeats Fad Diets]”, Schorno 2026
Adventures in Dieting: How can you tell when the battle is over [retatrutide defeats fad diets]
“The Power of Three: Retatrutide’s Role in Modern Obesity and Diabetes Therapy”, Abdul-Rahman et al 2024
The power of three: Retatrutide’s role in modern obesity and diabetes therapy
“‘Skinny Jabs’: Weight-Loss Drugs Set for New Boom As Generic Liraglutide Versions Emerge”, Davis & Kollewe 2024
‘Skinny jabs’: weight-loss drugs set for new boom as generic liraglutide versions emerge
“Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease: a Randomized Phase 2a Trial”, Sanyal et al 2024
“A Revolution in Obesity Treatment”, Lingvay & Agarwal 2023
“Goodbye, Ozempic: A New Class of Drugs Is Transforming Obesity Care. They Are Not All the Same”, Engber 2023
Goodbye, Ozempic: A new class of drugs is transforming obesity care. They are not all the same
“Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial: Supplement”, Jastreboff 2023
Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial: Supplement
“Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial”, Jastreboff et al 2023
Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial
“Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People With Type 2 Diabetes: a Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Phase 2 Trial Conducted in the USA”, Rosenstock et al 2023
xKloc @ "2022-12-13"
“Retatrutide, a Novel Triple GIP, GLP-1, and Glucagon Receptor Agonist in People With Type 2 Diabetes: a Phase 1b, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Multiple-Ascending Dose Trial”, Urva et al 2022
“LY3437943, a Novel Triple Glucagon, GIP, and GLP-1 Receptor Agonist for Glycemic Control and Weight Loss: From Discovery to Clinical Proof of Concept”, Coskun et al 2022
Sort By Magic
Annotations sorted by machine learning into inferred 'tags'. This provides an alternative way to browse: instead of by date order, one can browse in topic order. The 'sorted' list has been automatically clustered into multiple sections & auto-labeled for easier browsing.
Beginning with the newest annotation, it uses the embedding of each annotation to attempt to create a list of nearest-neighbor annotations, creating a progression of topics. For more details, see the link.
metabolic-therapy
weight-loss-drug obesity-trial triple-agonist phase-three obesity-research obesity-treatment
obesity-drugs weight-loss glycemic-control receptor-agonist diabetes-care retatrutide
Wikipedia (3)
Miscellaneous
Bibliography
https://www.theguardian.com/business/article/2024/jun/25/skinny-jabs-weight-loss-drugs-generic-ozempic-wegovy-saxenda: “‘Skinny Jabs’: Weight-Loss Drugs Set for New Boom As Generic Liraglutide Versions Emerge”,2023-lingvay.pdf: “A Revolution in Obesity Treatment”,https://www.theatlantic.com/health/archive/2023/06/ozempic-pills-obesity-drugs-semaglutide/674541/: “Goodbye, Ozempic: A New Class of Drugs Is Transforming Obesity Care. They Are Not All the Same”,